MajesTEC-2: Investigation of Teclistamab in Combination with Nirogacestat. 3 • Teclistamab. is the only . approved BCMA×CD3 bispecific antibody. with a personalized, weight-based,

2022年6月15日 · Teclistamab (JNJ-64007957) is a B-cell maturation antigen (BCMA) × CD3 T-cell redirecting bispecific antibody currently under investigation in patients with relapsed/refractory multiple myeloma (RRMM). Daratumumab (Dara) is a CD38-targeting monoclonal antibody with direct on-tumor and immunomodulatory mechanisms of action.

Background: Tec is the first BCMA-directed bispecific antibody approved for the treatment of triple-class exposed RRMM. Niro, a gamma secretase inhibitor, has been shown to potentiate BCMA-directed therapies in vitro and in clinical trials.

2022年6月10日 · Teclistamab is an investigational, fully humanized, T-cell redirecting, IgG4 bispecific antibody targeting both BCMA (B-cell maturation antigen) and CD3, the T-cell receptor.

2022年11月15日 · Introduction: Teclistamab (tec) is an off-the-shelf, B-cell maturation antigen (BCMA) × CD3 bispecific antibody that redirects CD3+ T cells to mediate T-cell activation and subsequent lysis of BCMA-expressing multiple myeloma (MM) cells.

2024年7月19日 · Discuss the data presented at EHA 2024 on the efficacy and safety of teclistimab in patients with relapsed/refractory multiple myeloma (RRMM) with high-risk features: a subgroup analysis of the...

2022年6月2日 · Background: Tec (JNJ-64007957) is a BCMA x CD3 bispecific antibody (Ab) that redirects CD3+ T cells to mediate T-cell activation and subsequent lysis of BCMA-expressing myeloma cells. MajesTEC-1 is a multicohort, open-label phase 1/2 study of tec in pts with RRMM who previously received ≥3 prior lines of therapy (LOT).

2023年5月31日 · Background: Tec is the first BCMA-directed bispecific antibody approved for the treatment of triple-class exposed RRMM. Tal, a bispecific antibody targeting the novel myeloma antigen GPRC5D, has shown promising efficacy in pts with RRMM.

2020年1月4日 · 关于EHA的定义，此处的直驱容积控制技术，直驱强调了直接控制而非间接（管路）控制，容积控制则强调了泵控而非阀控；此处的集成化动力执行器，明确了EHA它应该是泵、缸一体化装置。 人们经常拿泵控与阀控在性能上相比较，探讨到底泵控能达到什么样的水平。 参考主流厂家的产品，控制精度大多在0.01mm左右，响应时间几十ms，频宽一般在20~30Hz，因此与阀控超过可到几微米，几毫秒，超过100Hz的控制相比，泵控还是还是有不少差距的。 市面上 …

Wir sind auf die Steuerungstechnik für Automatisierungsanlagen spezialisiert und optimieren Ihre Prozesse durch die richtige Automatisierungs-Lösung.